000 | 01205 a2200349 4500 | ||
---|---|---|---|
005 | 20250517195158.0 | ||
264 | 0 | _c20190318 | |
008 | 201903s 0 0 eng d | ||
022 | _a1750-1172 | ||
024 | 7 |
_a10.1186/s13023-018-0761-2 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aStein, Susan | |
245 | 0 | 0 |
_aPrinciples for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organizations in the field of rare diseases. _h[electronic resource] |
260 |
_bOrphanet journal of rare diseases _c01 2018 |
||
300 |
_a18 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 | _aDecision Making |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aPatient Advocacy |
650 | 0 | 4 | _aPublic Health |
650 | 0 | 4 | _aRare Diseases |
700 | 1 | _aBogard, Elizabeth | |
700 | 1 | _aBoice, Nicole | |
700 | 1 | _aFernandez, Vivian | |
700 | 1 | _aField, Tessa | |
700 | 1 | _aGilstrap, Alan | |
700 | 1 | _aKahn, Susan R | |
700 | 1 | _aLarkindale, Jane | |
700 | 1 | _aMathieson, Toni | |
773 | 0 |
_tOrphanet journal of rare diseases _gvol. 13 _gno. 1 _gp. 18 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1186/s13023-018-0761-2 _zAvailable from publisher's website |
999 |
_c28003258 _d28003258 |